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ORIGINAL CONTRIBUTIONSComparison of 3 intranasal mists
for anesthetizing maxillary teeth
in adults
A randomized, double-masked, multicenter phase 3
clinical trialABSTRACT
Background. This double-masked, parallel-design,
clinical trial assessed whether a combination nasal spray
(K305; 3% tetracaine hydrochloride and 0.05% oxy-Sebastian G. Ciancio, DDS; Adam D. Marberger, DDS;
Fadi Ayoub, DDS; Davis A. Garlapo, DDS; Eugene A.
Pantera Jr., DDS, MS; Carole T. Pantera, DDS, MS;
Sultan Al-Mubarak, BDS, MD Sc, PhD; Benita D. Sobieraj,
DDS; David Y. He, MS; Srinivas R. Myneni, DDSmetazoline hydrochloride) compared with a tetracaine-
only spray and a placebo spray would be safer and superior
in producing local anesthesia sufﬁcient to complete a direct
restorative procedure in maxillary nonmolar teeth.
Methods. The authors randomized eligible patients to
receive K305 spray (n ¼ 44), tetracaine hydrochloride
spray (n¼ 44), or a placebo solution (n¼ 22). The authors
compared the incidence of the primary efﬁcacy end point—
completion of the procedure without rescue local anes-
thetic—by means of a 1-tailed Fisher exact test.T he most common method of anesthetizing amaxillary tooth is intraoral supraperiosteal in-jection of local anesthetic, commonly referred toas maxillary inﬁltration. Although this procedure
is effective, the need for injection carries several draw-
backs that can complicate treatment.
Fear of painful injections and subsequent avoidance
behavior are signiﬁcant barriers to regular dental care.1Copyright ª 2016 American Dental Assoc
article under the CC BY-NC-ND license (h
licenses/by-nc-nd/4.0/).
Results. The end point incidence was 84.1% (95% con-
ﬁdence interval [CI], 69.9-93.4) with K305, 27.3%
(95% CI, 15.0-42.8) with tetracaine only, and 27.3% (95%
CI, 10.7-50.2) with placebo (P < .001 for K305 versusAn estimated 30 to
40 million Americans
avoid visiting the
dentist because of feartetracaine only and versus placebo). Combination spray
was associated with statistically signiﬁcant but transient
increases in blood pressure. The most frequent adverse
events were rhinorrhea and nasal congestion, which
resolved within 2 hours after treatment and occurred more
often in the K305 group and tetracaine-only group.
Conclusions. In this study population, the K305 com-
bination nasal spray was safe and more effective in
attaining pulpal anesthesia of maxillary teeth from pre-
molar to premolar compared with tetracaine-only and
placebo sprays.
Practical Implications. The combination nasal spray
might represent a valuable alternative to injected local
anesthetic for patients undergoing invasive maxillary
dental procedures.
Key Words. Anesthesia; clinical trial; nasal spray;of pain and anesthetic injections.2-4 Injection of dental
anesthetic also carries the occupational hazard of possible
exposure to blood-borne pathogens via needlestick. To
reduce this risk, Congress passed the Needlestick Safety
and Prevention Act,5 which requires the use of needle-free
technology whenever possible. This law provides in-
centives to develop anesthetics that can be delivered via
such technologies.
Even with perfect administration technique, the onset,
effectiveness, and duration of maxillary inﬁltration
anesthesia can vary widely among patients. Success rates
can range from 65% to 100%; time between injection and
onset of anesthesia can range from 2 to 5 minutes in the
maxillary arch; and duration of pulpal anesthesia can
range from 10 to 100 minutes.6-17 In a survey of 93 general
practitioners, 42% of respondents reported at least 1iation. This is an open access
ttp://creativecommons.org/
tetracaine hydrochloride; oxymetazoline hydrochloride.
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ABBREVIATION KEY. BPM: Beats per minute. ND: Not
done. SNA: Subjective numbness assessment. STAA: Soft-
tissue anesthesia assessment.
ORIGINAL CONTRIBUTIONSanesthetic failure in maxillary posterior teeth, and 26%
reported at least 1 failure in maxillary anterior teeth.18
Inﬁltration injection may fail because of individual var-
iations in response to the drug administered, cortical
plate bone density, tissue vascularity, and neuroanatomy.
An anesthetic procedure that obviates the need for
injection could beneﬁt both patients and practitioners.
For many years, practitioners have used nasally applied
compounds to anesthetize tissues before diagnostic
and surgical otolaryngological procedures.19-24 For pro-
cedures involving the nasal cavity, practitioners often
add a vasoconstrictor such as oxymetazoline hydro-
chloride to reduce swelling and the risk of experiencing
bleeding.19 In a phase 2 study of combination tetracaine–
oxymetazoline spray, 83% of patients receiving the spray
required no rescue anesthesia via lidocaine injection.25
Among procedures involving maxillary nonmolar teeth,
the success rate was even higher (90%), and the spray
was safe and well tolerated.25 Initial phase 3 testing
showed similar success rates—88% for the combination
spray versus 28% for placebo spray.26
The objective of this phase 3 study was to determine
the efﬁcacy and safety of combination tetracaine–
oxymetazoline nasal spray (K305) compared with an
active control (tetracaine-only spray) and a placebo spray
for anesthetizing maxillary teeth in adults.
METHODS
This was a multicenter, randomized, double-masked,
parallel-group clinical trial comparing a combination
nasal anesthetic spray (K305 [also called Kovanaze],
St. Renatus) with a tetracaine-only spray and with a pla-
cebo spray among adults undergoing a dental procedure
in a maxillary nonmolar tooth. We recruited patients
seeking treatment at the University at Buffalo, The State
University of New York, Buffalo, NY (n ¼ 50) (center 1),
and at Family and Cosmetic Dentistry, Salt Lake City,
Utah (n ¼ 60) (center 2). We conducted this study in
compliance with the approval of the institutional review
board at each center.
Inclusion criteria. We included patients 18 years or
older who required local anesthesia for a restorative
dental procedure in 1 vital maxillary nonmolar tooth.
Patients could have no evidence of pulpal pathology.
They were required to be able to give informed consent
and understand and comply with the protocol’s re-
quirements; have a patent naris ipsilateral to the target
tooth; have a resting heart rate of 55 to 100 beats per
minute; and have a systolic blood pressure of 95 to 140
millimeters of mercury and a seated diastolic blood
pressure of 60 to 90 mm Hg.
Exclusion criteria. We excluded patients who had
inadequately controlled thyroid disease; 5 or more
nosebleeds each month; allergy or intolerance to any
study drug or preparation ingredient; or congenital or
idiopathic methemoglobinemia. We also excluded340 JADA 147(5) http://jada.ada.org May 2016patients who had received a monoamine oxidase inhib-
itor within the previous 3 weeks or who had used a nasal
spray or decongestant on the day of the study procedure.
Study procedures. An independent statistician pre-
pared a computer-generated randomization schedule in
blocks, within which we assigned annotations for treat-
ment groups. We numbered each drug kit in randomiza-
tion order and assigned it to a study center on shipment.
We assigned a sequential number to each patient who met
the eligibility criteria, and these numbers determined the
kit assignments. Therefore, the patients, investigators
(S.C., A.M., D.G., S.B., F.A., S.A., S.M.), and the investi-
gation team members who administered the spray (A.M.,
C.P., E.P.) all were masked as to the treatment adminis-
tered. At the Buffalo site, 2 members of the investigation
team (C.P., E.P.) administered the spray, and at the Utah
site, the investigator (A.M.) administered the spray.
We randomly assigned patients in a 2:2:1 ratio to
receive a total of 3 intranasal sprays (BD Accuspray nasal
spray system, Becton, Dickinson and Company) of 200
microliters each of K305, tetracaine-only, or placebo
spray ipsilateral to the treatment tooth, each given at
4 ( 1) minute intervals. The K305 spray contained
3% tetracaine hydrochloride and 0.05% oxymetazoline
hydrochloride. The 3-spray dose (600 mL) therefore
contained 18 milligrams tetracaine hydrochloride and
0.3 mg oxymetazoline hydrochloride. The tetracaine-only
spray was a 3% tetracaine hydrochloride solution,
and the 3-spray dose contained 18 mg of the drug. The
placebo spray was identical to the active treatments in
volume and administration technique. All 3 sprays were
clear, colorless, odorless, and tasteless aqueous solutions.
At mean (standard deviation [SD]) 15 (3) minutes
after administering the ﬁrst spray dose, the investigators
measured pulpal anesthesia by means of a subjective
numbness assessment (SNA) (Appendix 1, available on-
line at the end of this article) and performed a soft-tissue
anesthesia assessment (STAA) (Appendix 2, available
online at the end of this article) with a periodontal
probe (PDT Sensor Probe, DenMat) on the incisive
papilla and greater palatine foramen. If the investigator
deemed the patient’s dental anesthesia to be sufﬁcient,
the investigator began the procedure with a test drill.
If the investigator deemed the patient’s dental anesthesia
to be insufﬁcient, the investigator delayed the procedure
another 5 minutes, at which time, the investigator
repeated the SNA and STAA. If the anesthesia remained
insufﬁcient, the investigator immediately administered
rescue anesthetic, consisting of up to 3.4 milliliters of
articaine hydrochloride 4% with epinephrine 1:200,000.
Assessed for eligibility (n = 136)
Did not meet inclusion or
exclusion criteria (n = 26)
Randomized (n = 110)
Center 1 (n = 50)
Center 2 (n = 60)
K305 spray (n = 44)
• Received drug (n = 44)
Lost to follow-up (n = 0) Lost to follow-up (n = 0) Lost to follow-up (n = 0)
Analyzed (n = 44)
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Figure 1. Flowchart indicating disposition of patients.
ORIGINAL CONTRIBUTIONSThe investigators
measured vital signs,
noted the results of the
SNA and STAA, and
documented the inci-
dence of adverse events
every 15 ( 3) minutes
for an hour after the ﬁrst
dose of study drug, then
at mean (standard devi-
ation) 90 ( 3) minutes.
The investigators also
performed a participant-
reported safety assess-
ment (Appendix 3,
available online at the
end of this article), naris
examination, and alcohol
sniff test at 120 ( 3)
minutes after the ﬁrst
dose of the study drug
and at the next-day
follow-up visit.
Statistical ana-
lysis. The primary end
point was the success
rate, which we deﬁned
as completion of the
dental procedure without
the use of a rescue in-
jection of local anes-
thetic. We expected the
success rate to be
approximately 83% with K305 spray.25 Because each
pairwise comparison was a 1-tailed test, we set the type I
error (a) for each test at 0.025 (that is, 0.05/2). We
determined that the study results were to be declared
positive only if we could show that K305 was superior to
both tetracaine-only and placebo sprays. We set the type
II error (b) at 0.10. We determined that the power of the
study results to detect a 50% relative difference in success
rate for K305 spray versus tetracaine only and versus
placebo was to be at least 90%. We determined that the
intended sample sizes—44 patients in the K305 group, 44
patients in the tetracaine-only group, and 22 patients in
the placebo group—were sufﬁcient to detect such dif-
ferences at the desired power and a levels. We computed
power using StatXact 8 (Cytel) for Fisher exact test
comparing 2 binomial proportions. We included all
randomized patients in the analyses.
The secondary efﬁcacy end points were the incidence,
time of onset, and duration of soft-tissue anesthesia as
assessed by the results of the STAA. We deﬁned onset as
the time from completion of dosing to the time that the
patient reported no pain on pressure probing at the
incisive papilla and greater palatine foramen. We deﬁnedduration as the time from anesthesia onset to the time
the patient reported pain on soft-tissue pressure probing.
During a preliminary post hoc analysis, we noticed
that a disproportionate number of patients at study
center 1 had reported no pain on pressure probing, even
before treatment. Additional investigation revealed
confusion over the question’s wording—the expected
baseline answer was “yes,” in contrast with expected
baseline answer to the other study questions. As far as we
could determine, the STAA was the only assessment that
generated such confusion. Because of the questionable
baseline data for the STAA at this study center, we could
not deﬁne the onset and duration for a large number of
patients. We therefore conducted a post hoc analysis of
STAA results, stratiﬁed by study center.
We also conducted exploratory analyses of homoge-
neity of treatment effect across subgroups. We used the
Breslow-Day test to assess homogeneity in treatment
effect with regard to study center, tooth type (anterior
versus premolar), age, sex, ethnicity, and weight.
We assessed predeﬁned changes in heart rate and
blood pressures through the next-day follow-up visit. We
also compared the mean maximum change from baselineJADA 147(5) http://jada.ada.org May 2016 341
TABLE 1
Demographic and baseline characteristics of patients.
CHARACTERISTIC K305 SPRAY
(N [ 44)
TETRACAINE-ONLY
SPRAY (N [ 44)
PLACEBO SPRAY
(N [ 22)
P VALUE
Sex, No. (%) .011
Male 14 (31.8) 28 (63.6) 10 (45.5)
Female 30 (68.2) 16 (36.4) 12 (54.5)
Race, No. (%) .267
White 35 (79.5) 36 (81.8) 13 (59.1)
Black 2 (4.5) 3 (6.8) 2 (9.1)
Asian 1 (2.3) 2 (4.5) 4 (18.2)
Native Hawaiian/Paciﬁc Islander 2 (4.5) 0 (0) 1 (4.5)
Other 4 (9.1) 3 (6.8) 2 (9.1)
Ethnicity, No. (%) .876
Hispanic or Latino 3 (6.8) 2 (4.5) 1 (4.5)
Not Hispanic or Latino 41 (93.2) 42 (95.5) 21 (95.5)
Medical History, No. (%) ND*
Hypertension 4 (9.1) 2 (4.5) 4 (18.2)
Seasonal allergy 9 (20.5) 11 (25.0) 5 (22.7)
Exercise-induced asthma 2 (4.5) 2 (4.5) 2 (9.1)
Current smoking 11 (25.0) 10 (22.7) 5 (22.7)
Dental Pathology, No. (%) ND
Caries 32 (72.7) 34 (77.3) 18 (81.8)
Recurrent decay 12 (27.3) 7 (15.9) 4 (18.2)
Fracture 4 (9.1) 4 (9.1) 2 (9.1)
Target Tooth Number, No. (%) ND
4 (second premolar) 6 (13.6) 7 (15.9) 2 (9.1)
5 (ﬁrst premolar) 7 (15.9) 8 (18.2) 5 (22.7)
6 (canine) 3 (6.8) 2 (4.5) 2 (9.1)
7 (lateral incisor) 3 (6.8) 2 (4.5) 2 (9.1)
8 (central incisor) 2 (4.5) 5 (11.4) 2 (9.1)
9 (central incisor) 3 (6.8) 5 (11.4) 4 (18.2)
10 (lateral incisor) 5 (11.4) 3 (6.8) 0 (0)
11 (canine) 1 (2.3) 3 (6.8) 0 (0)
12 (ﬁrst premolar) 4 (9.1) 2 (4.5) 3 (13.6)
13 (second premolar) 10 (22.7) 7 (15.9) 2 (9.1)
Age, y, Mean (SD†) 37.1 (14.73) 31.3 (12.01) 35.7 (14.64) .128
Height, Centimeters, Mean (SD) 167.3 (8.38) 175.5 (8.88) 169.4 (9.19) < .001
Weight, Kilograms, Mean (SD) 85.2 (23.3) 82.6 (21.1) 80.8 (19.2) .718
* ND: Not done.
† SD: Standard deviation.
TABLE 2
Primary end point results: completion of dental
procedure without need for rescue local anesthetic.
RESULT K305 SPRAY
(N [ 44)
TETRACAINE-ONLY
SPRAY (N [ 44)
PLACEBO SPRAY
(N [ 22)
No. (%) of
Patients
95% CI* No. (%) of
Patients
95% CI No. (%) of
Patients
95% CI
Success 37 (84.1) 69.9-93.4 12 (27.3) 15.0-42.8 6 (27.3) 10.7-50.2
Failure 7 (15.9) ND† 32 (72.7) ND 16 (72.7) ND
P Value —‡ < .001§ < .001§
* CI: Conﬁdence interval.
† ND: Not done.
‡ Not applicable.
§ Versus K305 spray; 1-sided Fisher exact test.
ORIGINAL CONTRIBUTIONS
342 JADA 147(5) http://jada.ada.org May 2016in heart rate and blood pres-
sures by means of analysis of
variance, with treatment group
and study center as factors.
We used the same method
to analyze ﬁndings from the
alcohol sniff test from the
next-day follow-up visit.
We compared proﬁles
over time for heart rate and
blood pressures by means of
repeated-measures analysis
of covariance (implemented
by using SAS/STAT PROC
MIXED, SAS Institute) with
treatment, time, study center,
and prestudy vital sign mea-
surements as ﬁxed effects and
patient as a random effect.
We assessed the incidence
and relationship to the study
drug through the next-day
follow-up visit for adverse
events and through 30 days
for serious adverse events.
RESULTS
Patients. Between October
2012 and February 2013, we
screened 136 patients, of whom
we randomized 110 as previ-
ously described, and all pa-
tients completed their dental
procedure and study assess-
ments (Figure 1). One patient
in the tetracaine-only group
had a change in the target
tooth (from tooth no. 11 to tooth
no. 6), but no other major
protocol violations occurred.
Four dentists (A.M., B.S., D.G.,
F.A.) placed the restorations.
The patients’ mean age
was 34.5 years, and 76.4% were
white (Table 1). The tetracaine-
only group included signiﬁ-
cantly more men, and the
mean height was signiﬁcantly
greater in this group as well.
The most frequent pathology
in the target tooth was caries,
with recurrent decay and tooth
fractures accounting for the
remainder. Target teeth (each
patient had only 1 target tooth)
were distributed similarly
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Figure 2. Proportions of patients at center 2 reporting no pain from probing pressure at the incisive papilla
(A) and greater palatine foramen (B) over time with K305 spray, tetracaine-only spray, or placebo spray, in post
hoc analysis. Data at 30 minutes are not shown because of the large number of missing data points (patients were
still undergoing the dental procedure). Vertical lines denote 95% conﬁdence intervals. min: Minutes.
ORIGINAL CONTRIBUTIONSbetween the left and right
sides, with premolars
predominating. Intraoral
examinations were
normal for all patients
except for 1 patient in the
placebo group who
showed localized gingival
enlargement.
Primary end point.
In all, 84.1% of the pa-
tients who received K305
completed their class IV
restoration without the
need for rescue anes-
thesia, compared with
27.3% of patients in both
the tetracaine-only and
placebo groups (Table 2;
P < .001 for K305 versus
each of the other treat-
ments). For patients
requiring rescue anes-
thesia, the injection was
given at similar mean
times: 16.0 minutes, 15.2
minutes, and 16.3 mi-
nutes after the ﬁrst dose
of K305, tetracaine-only,
and placebo spray,
respectively.
Secondary end
points. At the prestudy
visit, most patients re-
ported pain on pressure
probing at the incisive
papilla and greater pala-
tine foramen. Beginning
at 15 minutes after the
ﬁrst dose of the study
drug, and continuing
through the 90-minute
assessment, the propor-
tion of patients reporting no pain at the incisive papilla
was highest in the K305 group (77.3% at 15 minutes versus
47.7% for tetracaine only and 36.4% for placebo). At the
120-minute and next-day follow-up visits, the pro-
portions of patients reporting no pain at this site were
similar across treatment groups. For the greater palatine
foramen, the proportions of patients reporting no pain
were smaller (compared with the incisive papilla) and
similar among groups at all time points.
In post hoc analysis of data from center 2 (see
Methods; Figure 2), all patients reported pain from
probing pressure in both oral locations before drug
administration. Onset of anesthesia in the incisivepapilla occurred at mean (SD) 9.7 (7.5) minutes in
the K305 group (n ¼ 22), 19.5 (17.6) minutes in the
tetracaine-only group (n ¼ 13), and 37.0 (0.0) minutes
in the placebo group (n ¼ 3; no P value calculated).
Anesthesia persisted for mean (SD) 79.2 (27.0) minutes,
32.1 (15.2) minutes, and 26.0 (17.3) minutes, respectively
(no P value calculated). At 15 minutes, anesthesia of
the incisive papilla was present in 79.2%, 33.3%, and 0%
of patients in the K305, tetracaine-only, and placebo
groups, respectively (P < .001). At 60, 90, and 120
minutes, these proportions had decreased somewhat
but remained signiﬁcantly different by treatment.
Anesthesia at the greater palatine foramen occurred atJADA 147(5) http://jada.ada.org May 2016 343
TABLE 3
Adverse events and vital sign–related end points, by
treatment.
EVENT K305 SPRAY
(N [ 44)
TETRACAINE-ONLY
SPRAY
(N [ 44)
PLACEBO
SPRAY
(N [ 22)
No. (%) of
Patients
No. (%) of Patients No. (%) of
Patients
Rhinorrhea 17 (38.6) 17 (38.6) 0 (0)
Nasal Congestion 15 (34.1) 27 (61.4) 3 (13.6)
Nasal Discomfort 11 (25.0) 5 (11.4) 1 (4.5)
Lacrimation Increased 7 (15.9) 4 (9.1) 0 (0)
Oropharyngeal Pain 6 (13.6) 4 (9.1) 0 (0)
Headache 6 (13.6) 1 (2.3) 1 (4.5)
Procedural Pain 6 (13.6) 22 (50.0) 13 (59.1)
Hypoesthesia 5 (11.4) 17 (38.6) 5 (22.7)
Throat Irritation 4 (9.1) 1 (2.3) 0 (0)
Paresthesia 4 (9.1) 0 (0) 0 (0)
Bradycardia 4 (9.1) 2 (4.5) 1 (4.5)
Hypertension 4 (9.1) 1 (2.3) 1 (4.5)
Rhinalgia 3 (6.8) 2 (4.5) 0 (0)
Upper-airway Cough Syndrome 3 (6.8) 2 (4.5) 0 (0)
Tachycardia 3 (6.8) 2 (4.5) 0 (0)
Toothache 2 (4.5) 10 (22.7) 5 (22.7)
Dysgeusia 2 (4.5) 1 (2.3) 0 (0)
Sinus Headache 2 (4.5) 0 (0) 0 (0)
Vital Sign–Related End Points
Heart rate < 50 bpm* 1 (2.3) 2 (4.5) 0 (0)
Heart rate > 125 bpm 1 (2.3) 0 (0) 0 (0)
Decrease in systolic blood pressure
of $ 15 mm Hg† and to < 90 mm Hg
0 (0) 0 (0) 0 (0)
Increase in systolic blood pressure
of $ 25 mm Hg and to > 160 mm Hg
2 (4.5) 1 (2.3) 0 (0)
Decrease in diastolic blood pressure
of $ 10 mm Hg and to < 50 mm Hg
1 (2.3) 0 (0) 0 (0)
Increase in diastolic blood pressure
of $ 15 mm Hg and to > 105 mm Hg
1 (2.3) 0 (0) 0 (0)
* bpm: Beats per minute.
† mm Hg: Millimeters of mercury.
ORIGINAL CONTRIBUTIONSmean (SD) 15.5 (11.4) minutes in the K305 group
(n ¼ 14), 24.6 (17.6) minutes in the tetracaine-only
group (n ¼ 13), and 29.5 (15.0) minutes in the placebo
group (n ¼ 4), and persisted for 45.9 (36.3) minutes,
35.4 (22.6) minutes, and 31.8 (29.5) minutes, respectively
(no P values calculated).
Results of Breslow-Day tests for homogeneity revealed
no signiﬁcant differences in treatment effect according to
study center, age, sex, or ethnicity. The beneﬁt of K305
over placebo was signiﬁcantly greater in anterior teeth—
a success rate of 17 of 17 (100%; 95% conﬁdence interval
[CI], 80.5-100) versus 1 of 10 (10%; 95% CI, 0.3-44.5),
respectively—than in premolars (20 of 27 [74.1%; 95% CI,
53.7-88.9] versus 5 of 12 [41.7%; 95% CI, 15.2-72.3];
P ¼ .006). The incremental beneﬁt of using K305 versus
tetracaine alone did not vary signiﬁcantly by type.344 JADA 147(5) http://jada.ada.org May 2016Safety end points. All but 2
patients (1 each in the K305 and
placebo groups) had at least 1
adverse event, neither of which
led to discontinuing the pa-
tients’ participation in the study
or death. The most common
adverse events were rhinorrhea,
nasal congestion, and nasal
discomfort, of which most were
considered mild (Table 3). Four
patients in the K305 group had 5
severe events: 1 each of nasal
discomfort, oropharyngeal pain,
rhinalgia, sneezing, and throat
irritation. Three patients in the
tetracaine-only group also had
severe events: 1 had toothache,
and 1 had procedural pain.
Another patient was the only
study participant to have mul-
tiple serious adverse events—
orbital cellulitis requiring hos-
pitalization, headache, and
sinusitis—that occurred 10 days
after the patient’s dental proce-
dure. The investigator (S.C.)
judged these latter events to be
remotely related to treatment.
The incidence of vital sign–
related end points was low
across treatment groups
(Table 3). For heart rate, the
mean values over time and
mean maximum changes did
not differ signiﬁcantly among
groups (P ¼ .30 and .49,
respectively; Figure 3). For sys-
tolic blood pressure, the mean
over time did differ signiﬁcantlyamong groups (P < .002; Figure 4), as did the mean
(SD) maximum change in the K305 group (13.7 [10.74]
mm Hg) versus the placebo group (5.1 [9.32] mm Hg;
P ¼ .004). For diastolic blood pressure, the mean over
time did not differ by treatment (P ¼ .133), but the
mean (SD) maximum change was again signiﬁcantly
higher in the K305 group (10.5 [7.12] mm Hg) than in
the tetracaine-only (7.3 [4.96] mm Hg) or placebo group
(6.7 [4.91] mm Hg; P ¼ .013). The increases in blood
pressure observed in the K305 group were transient in
all but 1 patient, asymptomatic, and required no medical
intervention.
Posttreatment olfactory sensitivity, assessed by
results of the alcohol sniff test, decreased slightly in all
patients after drug administration. By the next-day
follow-up visit, sensitivity had continued to decrease in
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ORIGINAL CONTRIBUTIONSthe tetracaine-only and
placebo groups, whereas it
had returned slightly
toward baseline in the
K305 group. Nasal exami-
nations revealed no major
clinical ﬁndings by the
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Figure 3. Mean heart rate over time in the K305, tetracaine-only, and placebo groups. Vertical lines denote 95%
conﬁdence intervals. bpm: Beats per minute.
160
K305 Spray Placebo SprayTetracaine-Only Spray
SY
ST
O
LI
C
B
LO
O
D
P
R
ES
SU
R
E
(m
m
 H
g)
D
IA
ST
O
LI
C
B
LO
O
D
P
R
ES
SU
R
E
(m
m
 H
g)
TIME BEFORE AND AFTER FIRST STUDY DRUG DOSE
140
120
100
80
60
40
Prestudy
(n = 110)
10 min
(n = 110)
30 min
(n = 34)
45 min
(n = 96)
60 min
(n = 110)
90 min
(n = 110)
120 min
(n = 109)
Figure 4.Mean systolic and diastolic blood pressures over time in the K305, tetracaine-only, and placebo groups.
Vertical lines denote 95% conﬁdence intervals. mm Hg: millimeter of mercury.DISCUSSION
In this study, the use
of a combination
tetracaine–oxymetazoline
nasal anesthetic spray
permitted completion
of a restorative dental
procedure on a maxillary
nonmolar tooth without
the need for rescue local
anesthetic injection in
84.1% of cases, compared
with rates of 27.3% for
tetracaine-only and pla-
cebo sprays. Study par-
ticipants tolerated
all 3 treatments well.
The success rate with
the K305 combination
spray that we observed
in this study is nearly
identical to the success
rate revealed in a corre-
sponding multicenter
phase 3 trial, which
compared K305 with
placebo spray alone.26
In this study, the
beneﬁt of using K305
spray instead of the pla-
cebo was signiﬁcantly
greater in anterior teeth
than in premolars. This
phenomenon might
reﬂect genetic differences
among the study partici-
pants. For example,
although 3 branches of
the superior alveolar nerve—anterior, middle, and pos-
terior—can supply the maxillary teeth, the middle
branch (which is associated with premolars) is absent
in 30% to 54% of people.27 How the body compensates
for this absence is unknown and might vary, but this
nerve’s function might be replaced by another nerve for
which the combination spray is less effective. Experience
with the spray device in the future might allow more ofthe compound to reach the rear of the nasal cavity,
increasing the degree of anesthesia to the premolars
and possibly the molars.
K305 showed a large effect relative to placebo
and to tetracaine alone, thus allowing sufﬁcient statis-
tical power to detect differences despite small sample
sizes. In addition, K305 is not being developed as a
general substitute for dental anesthesia; to date, itJADA 147(5) http://jada.ada.org May 2016 345
ORIGINAL CONTRIBUTIONShas shown effects only in maxillary nonmolar teeth in
adults.
As might be expected with an intervention involving
nasal sprays, the most frequent adverse events were
rhinorrhea, nasal congestion, and nasal discomfort, most
of which were considered mild. By the day after treat-
ment, most patients had returned to baseline status with
no clinically signiﬁcant problems manifest.
Mean maximum changes in blood pressure were
signiﬁcantly greater in the K305 group versus the
placebo group, counter to phase 2 ﬁndings.25 These
differences could be attributed to the mechanism of
action of oxymetazoline, a sympathomimetic drug that
selectively agonizes a1- and (partly) a2-adrenergic
receptors, causing vasoconstriction.28 At the same time,
the placebo group showed marked decreases in blood
pressure, possibly related to the more frequent use of
rescue (articaine or epinephrine) injections in this
group.29 Such decreases would have magniﬁed any
potential hypertensive effects of oxymetazoline. In any
event, these changes in blood pressure were generally
transient, as in a previous pharmacokinetic study,30
and required no intervention.
Although we attempted to minimize the possibility
of bias through randomization and double-masking, we
noticed that a discrepancy emerged between study cen-
ters regarding how investigators conducted the STAA.
We therefore performed both the intention-to-treat
analysis and a post hoc analysis from the study center
that had more complete data. We also did not control for
possible interobserver variability in some assessments
(for example, nasal examination for inﬂammation or
ulceration). Such variables were secondary end points,
however, and should not have inﬂuenced the main
analyses.
Nasally administered anesthetic can preclude many of
the risks and drawbacks of injected anesthetics, for both
patients and practitioners, including needlesticks. In
addition, if the patient requires a more complicated
procedure, providers can administer additional palatal
anesthetic with a reduced possibility of pain in some
cases.
CONCLUSIONS
In this study, combination tetracaine–oxymetazoline
nasal spray was superior to tetracaine-only and placebo
sprays in producing anesthesia sufﬁcient to allow
completion of a direct dental restorative procedure on
a maxillary nonmolar tooth in adults. This novel com-
pound could offer a valuable alternative to injected local
anesthesia for patients and practitioners alike. n
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Restlessness Yes No
Dizziness Yes No
Confusion Yes No
Body Numbness Yes No
Tinnitus Yes No
Blurred Vision Yes No
Tremors Yes No
Nausea Yes No
Itching Yes No
Breathing Problems Yes No
Light-headedness Yes No
Metallic Taste Yes No
Numbness Around Mouth Yes No
Agitation Yes No
ORIGINAL CONTRIBUTIONSAPPENDIX 1: INSTRUCTIONS FOR SUBJECTIVE
NUMBNESS ASSESSMENT
To assess conditions that could be associated with
investigative drug, ask the study participant the following
questions:
-Do you notice any abnormal sensation when you tap
your front teeth together?
-Do you notice any abnormal sensation in the roof of
your mouth?
Record the response (yes or no) in the source
documents.
APPENDIX 2: INSTRUCTIONS FOR SOFT-TISSUE
ANESTHESIA ASSESSMENT
To assess soft-tissue anesthesia, use a mechanical
periodontal probe to exert pressure on the following:
- incisive papilla
- greater palatine foramen ipsilateral to the study
dental procedure.
For each site tested, ask the study participant, “Do you
feel any pain?” and record the response (yes or no) in the
source documents.
Testing at each of the 2 soft-tissue sites will take place
at baseline; at 15, 30, 45, 60, 90, and 120 minutes after the
procedure (unless pain is detected); and at the next-day
follow-up visit.347.e1 JADA 147(5) http://jada.ada.org May 2016APPENDIX 3: INSTRUCTIONS FOR PARTICIPANT-
REPORTED SAFETY EVALUATION
To assess conditions that could be associated with the
investigative drug, ask the study participant (and record
the responses in the source documents) the following
questions:
-Do you feel any different now than when you came in
for treatment today?
-Are you currently feeling or exhibiting any of the
following conditions?
